Isabella Ciccone, Content Associate, NeurologyLive®, has been with the team since September 2022. Follow her on X @iciccone7 or email her at iciccone@mjhlifesciences.com
Findings from the phase 3 OCEANIC-STROKE study showed that the addition of asundexian, a factor XIa inhibitor, with antiplatelet therapy lowered recurrent ischemic stroke compared with placebo.
An exploratory analysis of a phase 3 trial showed that solriamfetol improved daytime wakefulness without producing consistent or clinically meaningful changes in nocturnal sleep quality measures.
In honor of International Pompe Day, held April 15, 2026, NeurologyLive reviewed recent studies on the latest research and evolving standards of care for Pompe disease.
The approved neurofilament light chain test offers a minimally invasive approach to assessing neuroaxonal damage, with potential to complement MRI in routine multiple sclerosis care.
A recent study revealed that a substantial proportion of patients with NMOSD required escalation from first-line immunosuppressants to rituximab, with baseline severe disability emerging as a key associated factor.
A recent population-based data analysis of Korean adults reported those with anxiety and certain sleep disturbances experienced longer durations of morning grogginess, known as sleep inertia.
A recent study reported that relapse prevention was the most influential factor in treatment selection, with respondents favoring profiles similar to ravulizumab over other approved options for NMOSD.
Here's some of what is coming soon to NeurologyLive® this week.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending April 10, 2026.
The director of neuromuscular medicine at Marcus Neuroscience Institute shared findings from an analysis presented at MDA 2026 that compared real-world infection rates associated with generalized myasthenia gravis therapies. [WATCH TIME: 8 minutes]
In recognition of National Public Health Week, held April 6-12, NeurologyLive summarizes recent literature showing that environmental exposures are associated with increased risk of neurologic disorders.
The director of the Neurology Residency Program at the Marcus Neuroscience Institute talked about the role of research, patient empowerment, and expanding treatment options in multiple sclerosis. [WATCH TIME: 5 minutes]
A neuroimmunology fellow at the Cleveland Clinic shared her experience attending the 2026 ACTRIMS Forum, specifically focusing on the late-breaking data presented in multiple sclerosis.
The director of the Neurology Residency Program at the Marcus Neuroscience Institute discussed the importance of early recognition of invisible symptoms in comprehensive multiple sclerosis care. [WATCH TIME: 9 minutes]
Stay informed on the latest therapeutic advancements with this clinical recap from the NeurologyLive® team, featuring a centralized look at 7 FDA-approved treatments from the first quarter of 2026.
A new post hoc analysis of the CHAMPION-NMOSD trial reported similar safety and relapse prevention outcomes with ravulizumab-cwvz in patients with and without prior rituximab exposure.
Findings from a recently published study suggest peripapillary retinal nerve fiber layer thickness measured by OCT could support clinicians with early distinction between MOGAD-optic neuritis and NMOSD-optic neuritis.
Here's some of what is coming soon to NeurologyLive® this week.
A subpopulation analysis of the phase 2 ADHERE trial suggests clinical benefit and a favorable safety profile for efgartigimod PH20 in Chinese patients with chronic inflammatory demyelinating polyneuropathy.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending April 3, 2026.
An international real-world analysis highlighted prolonged time to diagnosis and common misdiagnoses in patients with chronic inflammatory demyelinating polyradiculoneuropathy.
A neuroimmunology fellow at the Cleveland Clinic reflected on the 2026 ACTRIMS Forum, highlighting key takeaways in multiple sclerosis research presented in the program. [WATCH TIME: 6 minutes]
A recent retrospective cohort analysis suggests newer NMOSD-specific treatments may offer improved efficacy and safety compared with rituximab and commonly used off-label therapies.
Catch up on any of the neurology headlines you may have missed in March 2026, compiled into 1 place by the NeurologyLive® team.
A case report of a 12-year-old boy highlighted a potential association between immunoglobulin G subclass imbalance and antibody detection in myelin oligodendrocyte glycoprotein antibody disease.
A cross-sectional study suggests excessive daytime sleepiness may represent an independent, nonmotor feature of idiopathic normal pressure hydrocephalus, separate from apnea or disease severity.
Constance V. Katsafanas, DO, director of the Neurology Residency Program at the Marcus Neuroscience Institute, highlighted the importance of individualized treatment strategies in multiple sclerosis.
The director of the Neurology Residency Program at the Marcus Neuroscience Institute detailed the importance of tailoring treatment to patients with multiple sclerosis. [WATCH TIME: 5 minutes]
Here's some of what is coming soon to NeurologyLive® this week.
A new obstructive sleep apnea study suggested that fatigue and objective daytime sleepiness are uncorrelated, challenging the use of the Epworth Sleepiness Scale as a measure of sleepiness.
